Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2015-11-20 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
POST-EFFECTIVE AMENDMENT NO.1
Regulatory Filings Classification · 95% confidence The document is titled 'Post-Effective Amendment No. 1 to Registration Statement' and references Form F-3, which is a registration statement under the Securities Act of 1933. It includes detailed information about exhibits, legal opinions, underwriting agreements, indentures, and officer certificates. The document is a filing related to securities registration and amendments to such registration statements, not a financial report, earnings release, or management discussion. It is a regulatory filing related to capital markets and securities registration, specifically a post-effective amendment to a registration statement. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it contains detailed legal and regulatory information rather than financial statements or report content.
2015-11-20 English
FINAL PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 100% confidence The document is titled 'FINAL PROSPECTUS SUPPLEMENT' and includes detailed information about the issuance of notes (debt securities) by Novartis Capital Corporation, including terms, interest rates, maturity dates, underwriting details, and registration fees. It references Rule 424(b)(5) under the Securities Act of 1933, which pertains to prospectus supplements for securities offerings. The content is focused on a capital raising transaction through debt issuance, describing the securities offered and underwriting arrangements. There is no indication that this is a financial report, earnings release, or management discussion. The document is a detailed disclosure related to a financing activity, specifically a debt offering. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length (15,000 characters) and detailed content confirm it is the actual prospectus supplement, not just an announcement or a brief summary.
2015-11-18 English
FWP
Capital/Financing Update Classification · 95% confidence The document is a Pricing Term Sheet filed pursuant to Rule 433, which is a type of Free Writing Prospectus (FWP) related to a securities offering. It details terms of notes issued by Novartis Capital Corporation, including coupon rates, maturity dates, redemption options, and ratings. The document is focused on capital raising and financing terms rather than financial results, management changes, or regulatory compliance. It is not a full financial report, earnings release, or management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (6394 characters) supports it being a detailed term sheet rather than a brief announcement or a full report.
2015-11-18 English
PRELIMINARY PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 95% confidence The document is titled as a "Preliminary Prospectus Supplement" filed pursuant to Rule 424(b)(5), which is a regulatory filing related to securities offerings. It details terms of notes due in 2025 and 2045, interest rates, redemption options, underwriting details, and legal disclaimers. The document is a supplement to a prospectus and is primarily focused on providing information about a debt securities offering by Novartis Capital Corporation guaranteed by Novartis AG. It is not a financial report, earnings release, or management discussion. It is a capital markets document related to financing activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, not just an announcement or a brief notice, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2015-11-17 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It includes a statement of computation of ratio of earnings to fixed charges as an exhibit. The document is relatively short (2653 characters) and primarily serves as a regulatory filing to provide information to the SEC and incorporate by reference into a registration statement. It does not contain comprehensive financial statements or detailed financial analysis typical of annual or interim reports. It also does not fit into other specific categories such as earnings release, management reports, or capital updates. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings like Form 6-K reports that do not fit other categories.
2015-11-17 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It references a financial report for Q3 2015 included as an exhibit but does not itself contain detailed financial statements or substantive financial data. The document length is 3082 characters, which is relatively short and mainly serves as an announcement or incorporation by reference of the financial report. According to the rules, such a document should be classified as a Regulatory Filing (RNS) because it is a regulatory announcement and not the full financial report itself.
2015-11-17 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.